Analysts Set Dolby Laboratories (NYSE:DLB) PT at $95.75

Shares of Dolby Laboratories (NYSE:DLB) have received a consensus rating of “Moderate Buy” from the six research firms that are presently covering the company, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $95.75.

DLB has been the topic of a number of recent analyst reports. Robert W. Baird initiated coverage on Dolby Laboratories in a report on Friday, September 5th. They set a “neutral” rating and a $74.00 price target on the stock. Barrington Research reiterated an “outperform” rating and set a $100.00 price target on shares of Dolby Laboratories in a report on Friday, September 12th. Tigress Financial lifted their price target on Dolby Laboratories from $112.00 to $114.00 and gave the stock a “buy” rating in a report on Friday, August 15th. Rosenblatt Securities reissued a “buy” rating and issued a $95.00 target price on shares of Dolby Laboratories in a research report on Friday, August 1st. Finally, Baird R W raised Dolby Laboratories to a “hold” rating in a research report on Friday, September 5th.

Dolby Laboratories Trading Down 0.3%

Shares of Dolby Laboratories stock opened at $71.27 on Wednesday. The business’s fifty day simple moving average is $72.64 and its 200 day simple moving average is $74.52. The firm has a market capitalization of $6.83 billion, a P/E ratio of 26.10 and a beta of 0.92. Dolby Laboratories has a 12 month low of $68.24 and a 12 month high of $89.66.

Dolby Laboratories (NYSE:DLB) last issued its quarterly earnings results on Thursday, July 31st. The electronics maker reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.72 by $0.06. The business had revenue of $315.55 million for the quarter, compared to analyst estimates of $305.23 million. Dolby Laboratories had a return on equity of 11.52% and a net margin of 19.62%.Dolby Laboratories’s quarterly revenue was up 9.2% compared to the same quarter last year. During the same period last year, the company posted $0.71 earnings per share. Dolby Laboratories has set its FY 2025 guidance at 3.880-4.030 EPS. Q4 2025 guidance at 0.610-0.760 EPS. Analysts predict that Dolby Laboratories will post 2.94 EPS for the current fiscal year.

Dolby Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, August 20th. Shareholders of record on Tuesday, August 12th were given a $0.33 dividend. This represents a $1.32 dividend on an annualized basis and a yield of 1.9%. The ex-dividend date of this dividend was Tuesday, August 12th. Dolby Laboratories’s dividend payout ratio (DPR) is currently 48.35%.

Insiders Place Their Bets

In other Dolby Laboratories news, SVP Shriram Revankar sold 7,000 shares of the firm’s stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $74.92, for a total value of $524,440.00. Following the completion of the sale, the senior vice president directly owned 70,435 shares of the company’s stock, valued at $5,276,990.20. This trade represents a 9.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Kevin J. Yeaman sold 25,000 shares of the firm’s stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $71.66, for a total value of $1,791,500.00. Following the completion of the sale, the chief executive officer directly owned 114,725 shares of the company’s stock, valued at $8,221,193.50. This represents a 17.89% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 99,366 shares of company stock valued at $7,293,963 over the last three months. Company insiders own 38.39% of the company’s stock.

Hedge Funds Weigh In On Dolby Laboratories

Hedge funds have recently made changes to their positions in the stock. Alpine Bank Wealth Management purchased a new position in shares of Dolby Laboratories in the first quarter valued at $25,000. Cheviot Value Management LLC purchased a new position in shares of Dolby Laboratories in the first quarter valued at $27,000. MAI Capital Management grew its position in shares of Dolby Laboratories by 87.1% in the first quarter. MAI Capital Management now owns 348 shares of the electronics maker’s stock valued at $28,000 after purchasing an additional 162 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in Dolby Laboratories during the first quarter valued at $29,000. Finally, Allworth Financial LP boosted its stake in Dolby Laboratories by 590.4% during the second quarter. Allworth Financial LP now owns 504 shares of the electronics maker’s stock valued at $37,000 after buying an additional 431 shares during the period. 58.56% of the stock is currently owned by hedge funds and other institutional investors.

About Dolby Laboratories

Dolby Laboratories, Inc creates audio and imaging technologies that transform entertainment at the cinema, DTV transmissions and devices, mobile devices, OTT video and music services, home entertainment devices, and automobiles. The company develops and licenses its audio technologies, such as AAC & HE-AAC, a digital audio codec solution used for a range of media applications; AVC, a digital video codec with high bandwidth efficiency used in various media devices; Dolby AC-4, a digital audio coding technology that delivers new audio experiences to a range of playback devices; and Dolby Atmos technology for cinema and various media devices.